Futura Medical Issues Shares for Non-Executive Director Remuneration

Futura Medical ( (GB:FUM) ) has issued an update.

Futura Medical announced the issuance of 126,116 new ordinary shares as part of the 2024 remuneration for its Non-Executive Directors, in line with their service agreements. These shares, priced at 27.10 pence each, are a portion of the directors’ compensation and will commence trading on AIM on January 16, 2025. This issuance increases the total number of voting rights to 303,829,684, influencing shareholder calculations under the FCA’s rules. This strategic move demonstrates Futura’s commitment to aligning director interests with company performance, potentially impacting its market position and stakeholder relations.

More about Futura Medical

Futura Medical plc is a pharmaceutical company specializing in the development and commercialization of innovative products for sexual health and pain relief. Its lead product, Eroxon, is a topical gel for erectile dysfunction, offering a unique over-the-counter solution for this widespread condition. Futura Medical has established distribution partnerships in major markets including the US and Europe, solidifying its position in the sexual health industry.

YTD Price Performance: -4.03%

Average Trading Volume: 663,585

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: £92.25M

For an in-depth examination of FUM stock, go to TipRanks’ Stock Analysis page.